Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses

Transplantation

Volumn 88, Issue 3, 2009, Pages 330-338

  Visner, Gary A ^a   Liu, Fengzhi ^a   Bizargity, Peyman ^a   Liu, Hanzhong ^a   Liu, Kaifeng ^a   Yang, Jun ^a   Wang, Liqing ^b   Hancock, Wayne W ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Rodent; T cells; Transplantation

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CHEMOKINE; CYTOKINE; ESTER; PIRFENIDONE; RAPAMYCIN; SUCCINIMIDE; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ALLOTRANSPLANTATION; ANIMAL CELL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; GRAFT SURVIVAL; HEART GRAFT; HISTOCOMPATIBILITY COMPLEX; IMMUNITY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; RECIPIENT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINES; CYTOKINES; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOSUPPRESSIVE AGENTS; ISOANTIGENS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRIDONES; SIROLIMUS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 69449098808     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ae3392     Document Type: Article

References (40)

1. Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54: 99. (Pubitemid 28288024)
2. Van Erp C, Irwin NG, Hoey AJ. Long-term administration of pirfenidone improves cardiac function in mdx mice. Muscle Nerve 2006; 34: 327. (Pubitemid 44300164)
3. Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 2006; 114: 1703. (Pubitemid 44607118)
4. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276(2 Pt 1): L311. (Pubitemid 29102273)
5. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040. (Pubitemid 40616955)
6. Giri SN, Wang Q, Xie Y, et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 2002; 23: 203. (Pubitemid 34812311)
7. Liu H, Drew P, Gaugler AC, et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 2005; 5: 1256. (Pubitemid 40839413)
8. Hirano A, Kanehiro A, Ono K, et al. Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am J Respir Cell Mol Biol 2006; 35: 366. (Pubitemid 44353405)
9. Shihab FS, Bennett WM, Yi H, et al. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2002; 2: 111. (Pubitemid 36306789)
10. Cain WC, Stuart RW, Lefkowitz DL, et al. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998; 20: 685.
11. Hale ML, Margolin SB, Krakauer T, et al. Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun 2002; 70: 2989. (Pubitemid 34564158)
12. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113: 72. (Pubitemid 28329068)
13. Nakazato H, Oku H, Yamane S, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002; 446: 177. (Pubitemid 34722572)
14. Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002; 446: 167. (Pubitemid 34722571)
15. Liu H, Drew P, Cheng Y, et al. Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. J Thorac Cardiovasc Surg 2005; 130: 852. (Pubitemid 41265730)
16. Dosanjh A, Ikonen T, Wan B, et al. Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther 2002; 15: 433. (Pubitemid 35339394)
17. Zhou H, Latham CW, Zander DS, et al. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. J Heart Lung Transplant 2005; 24: 1577. (Pubitemid 41396456)
18. McKane BW, Fernandez F, Narayanan K, et al. Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model. Transplantation 2004; 77: 664. (Pubitemid 38366969)
19. Dosanjh A. Pirfenidone: Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. Eur J Pharmacol 2006; 536: 219.
20. Di Filippo S, Zeevi A, McDade KK, et al. Impact of TGFbeta1 gene polymorphisms on acute and chronic rejection in pediatric heart transplant allografts. Transplantation 2006; 81: 934.
21. Shittu EA, Yang CP, Roberts IS, et al. Inhibition of chronic vascular rejection by donor-specific blood transfusion is associated with a reduction in transforming growth factor-beta1 expression. Transplantation 2002; 73: 1573.
22. Qin L, Chavin KD, Ding Y, et al. Gene transfer for transplantation. Prolongation of allograft survival with transforming growth factorbeta 1. Ann Surg 1994; 220: 508. (Pubitemid 24323446)
23. Hodge G, Hodge S, Chambers D, et al. Acute lung transplant rejection is associated with localized increase in T-cell IFN gamma and TNFalpha proinflammatory cytokines in the airways. Transplantation 2007; 84: 1452. (Pubitemid 350294720)
24. Csencsits K, Wood SC, Lu G, et al. Transforming growth factor-beta1 gene transfer is associated with the development of regulatory cells. Am J Transplant 2005; 5: 2378. (Pubitemid 43919420)
25. Hall BM. Cells mediating allograft rejection. Transplantation 1991; 51: 1141.
26. Bishop DK, Shelby J, Eichwald EJ. Mobilization of T lymphocytes following cardiac transplantation. Evidence that CD4-positive cells are required for cytotoxic T lymphocyte activation, inflammatory endothelial development, graft infiltration, and acute allograft rejection. Transplantation 1992; 53: 849.
27. Nozaki T, Rosenblum JM, Ishii D, et al. CD4 T cell-mediated rejection of cardiac allografts in B cell-deficient mice. J Immunol 2008; 181: 5257.
28. Suchin EJ, Langmuir PB, Palmer E, et al. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J Immunol 2001; 166: 973. (Pubitemid 32060253)
29. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
30. Frenken LA, Koene RA, Tax WJ. The role of antibody isotype in IFN-gamma and IL-2 production during anti-CD3-induced T cell proliferation. Transplantation 1991; 51: 881.
31. Hobbs MV, Weigle WO, Noonan DJ, et al. Patterns of cytokine gene expression by CD4 T cells from young and old mice. J Immunol 1993; 150(8 Pt 1): 3602.
32. Dosanjh AK, Wan B, Throndset W, et al. Pirfenidone: A novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis. Transplant Proc 1998; 30: 1910. (Pubitemid 28399365)
33. Antoshina E, Ostrowski LE. TGF beta 1 induces growth arrest and apoptosis but not ciliated cell differentiation in rat tracheal epithelial cell cultures. In Vitro Cell Dev Biol Anim 1997; 33: 212. (Pubitemid 27175047)
34. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84: 5788.
35. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006; 24: 99.
36. Wiseman DM, Polverini PJ, Kamp DW, et al. Transforming growth factor-beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988; 157: 793.
37. Prud'homme GJ. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007; 87: 1077.
38. Rubtsov YP, Rudensky AY. TGF beta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007; 7: 443.
39. Suda T, D'Ovidio F, Daddi N, et al. Recipient intramuscular gene transfer of active transforming growth factor-beta1 attenuates acute lung rejection. Ann Thorac Surg 2001; 71: 1651. (Pubitemid 32452561)
40. Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: Implications for transplantation. Transpl Immunol 2003; 11: 267. (Pubitemid 37120546)